Treatment of acute gouty arthritis in complex hospitalized patients with anakinra.

Abstract

OBJECTIVE:

To report our experience with the efficacy and safety of anakinra for acute gouty arthritis in medically complex hospitalized patients.

METHODS:

We reviewed the hospital charts of 26 patients treated with anakinra for crystal-induced arthritis since 2007. Demographics, comorbid conditions, reason for anakinra use, response to treatment, and any adverse outcomes were recorded.

RESULTS:

Twenty-six patients received 40 courses of anakinra therapy. In 67% of patients, pain improved significantly within 24 hours, and complete resolution of signs and symptoms of gout occurred by day 5 in 72.5% of patients. Seven patients received multiple courses with no decrement in response with repeated treatments. Anakinra was well tolerated and no adverse outcomes were attributed to the medication. Only 1 patient appeared to be refractory to this form of interleukin-1 inhibition.

CONCLUSION:

Anakinra is an effective and safe alternative treatment for acute gouty arthritis in medically complex hospitalized patients who fail or cannot undergo more conventional therapy.

• Authors: Pradipta Ghosh, Michael Cho, Gurpreet Rawat, Peter A Simkin, Gregory C Gardner
• Journal: Arthritis care & research (Arthritis Care Res (Hoboken)) Vol. 65 Issue 8 Pg. 1381-4 (Aug 2013) ISSN: 2151-4658 [Electronic] United States
• PMID: 23650178 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 by the American College of Rheumatology.

Chemical References

• Antirheumatic Agents
• Interleukin 1 Receptor Antagonist Protein

Topics

• Adult
• Aged
• Aged, 80 and over
• Antirheumatic Agents (therapeutic use)
• Arthritis, Gouty (complications, drug therapy)
• Female
• Hospitalization
• Humans
• Interleukin 1 Receptor Antagonist Protein (therapeutic use)
• Male
• Middle Aged
• Retrospective Studies